Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

CytomX

Roche Basel Switzerland

Roche faces biosimilar blitz in 2018

Analysts predict copycat competitors will slow the Swiss group’s revenue growth

- PMLiVE

Amgen set for Kyprolis label boost after CHMP backing

Multiple myeloma treatment set to add new survival data

- PMLiVE

Amgen and Allergan win first EU approval for Avastin biosimilar

Mvasi, their version of Roche's blockbuster, is licensed for six types of cancers

Sanofi reception

Sanofi and Regeneron ramp up immuno-oncology collaboration

Will put an additional $1bn in investigational candidate cemiplimab

- PMLiVE

Amgen gets prevention claim for cholesterol drug Repatha

FDA approves new labelling on heart attack and stroke risk reduction

Amgen appoints Wanda Austin to its Board

She will also serve as a member of the firm's audit committee

- PMLiVE

Amgen hopes its latest Kyprolis trial hits the mark with regulators

A.R.R.O.W study takes aim at once-weekly dosing regimen in multiple myeloma

Sanofi reception

US court lifts ban on sales of Sanofi’s Praluent

The duo can continue to compete against Amgen's rival PCSK9 Repatha

- PMLiVE

Amgen pledges $1.5bn for CytomX preclinical cancer drugs

Stellar valuations for immuno-oncology candidates continue

- PMLiVE

AbbVie deal with Amgen sets biosimilar Humira launch dates

Agreement will see Europe access the drug over four years earlier than patients in the US

- PMLiVE

Amgen’s Mvasi is first FDA-approved cancer biosimilar

Offers prospect of lower-cost alternative to Roche's Avastin

- PMLiVE

Amgen signs real world study and mobile data partnership

Will work with health and wellbeing group Humana on risk prevention

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links